Advertisement

Annals of Clinical Psychiatry

, Volume 9, Issue 1, pp 7–13 | Cite as

Retrospective Study of Selegiline–Antidepressant Drug Interactions and a Review of the Literature

  • Janet L. Ritter
  • Bruce Alexander
Article
  • 80 Downloads

Abstract

Selegiline is a selective monoamine oxidase inhibitor used in the treatment of Parkinson's disease. It is estimated that approximately one-half of Parkinsonian patients will develop depression requiring antidepressant drug treatment. Recently, selegiline's package insert was revised to reflect the potential risk of adverse effects when it is used in combination with selective serotonin reuptake inhibitors and tricyclic antidepressants. The objective of our study is to assess the safety of combining selegiline with antidepressants. A retrospective chart review was performed on all 28 patients with Parkinson's disease receiving selegiline and antidepressants concurrently to identify possible drug interactions. Compliance was assessed according to prescription refill records. Suspected adverse reactions with combination therapy were documented. There was a total of 40 selegiline–antidepressant drug combinations involving tricyclic antidepressants (n=25), selective serotonin reuptake inhibitors (n=7), trazodone (n=5), and bupropion (n=3). One patient receiving fluoxetine developed a reaction consistent with the serotonin syndrome; however, it was never documented as such. No other selegiline drug interactions were found. Adverse effects noted were typical of antidepressant monotherapy. Although no selegiline drug interactions were documented in our study, the concurrent administration of selegiline and selective serotonin reuptake inhibitors should be avoided because of literature-reported interactions. We believe that bupropion, tricyclic antidepressants, and trazodone are reasonable choices in combination with selegiline, although tricyclic antidepressants and trazodone may be reserved as second-line treatments.

Selegiline antidepressants selective serotonin reuptake inhibitors tricyclic antidepressants bupropion drug interactions 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Suchowersky O, deVries J: Possible interactions between Deprenyl and Prozac [letter]. Can J Neurol Sci 1990; 17:352–353Google Scholar
  2. 2.
    Blackwell B: Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991; 11:55–59Google Scholar
  3. 3.
    Davies G: Side effects of phenelzine [letter]. Br Med J 1960; 2:1019Google Scholar
  4. 4.
    Singh H: Atropine-like poisoning due to tranquilizing agents [letter]. Am J Psychiatry 1960; 117:360–361Google Scholar
  5. 5.
    Howarth E: Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment Sci 1961; 107:100–103Google Scholar
  6. 6.
    Ayd FJ: Toxic somatic and psychopathologic reactions to antidepressant drugs. J Neuropsychiatry 1961; 2:S119–S122Google Scholar
  7. 7.
    Selegiline (Eldepryl) Package Insert: Somerset Pharmaceuticals; Sept 1994Google Scholar
  8. 8.
    Sternbach H: The serotonin syndrome. Am J Psychiatry 1991; 148:705–713Google Scholar
  9. 9.
    McCurdy RL, Kane FJ: Transient brain syndrome as a nonfatal reaction to combined pargyline-imipramine treatment. Am J Psychiatry 1964; 121:397–398Google Scholar
  10. 10.
    Brachfeld J, Wirtschafter A, Wolfe S: Imipramine-tranylcypromine incompatibility [letter]. JAMA 1963; 186:1172–1173Google Scholar
  11. 11.
    Kane FJ, Freeman D: Non-fatal reaction to imipramine-MAO inhibitor combination [letter]. Am J Psychiatry 1963; 120:79–80Google Scholar
  12. 12.
    Babiak W: Case fatality due to overdosage of a combination of tranylcypromine and imipramine [letter]. Can Med Assoc J 1961; 85:377Google Scholar
  13. 13.
    Bowen LW: Fatal hyperpyrexia with antidepressant drugs. Br Med J 1964; 2:1465–1466Google Scholar
  14. 14.
    Ponto LB, Perry PJ, Liskow BI, Seaba HH: Drug therapy reviews: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 1977; 34:954–961Google Scholar
  15. 15.
    Blackwell B, Marley E, Price J: Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113:349–365Google Scholar
  16. 16.
    Goldberg RS, Thornton WE: Combined tricyclic-MAOI therapy for refractory depression: A review, with guidelines for appropriate usage. J Clin Pharmacol 1978; Feb.–Mar.:143–147Google Scholar
  17. 17.
    DRUGDEX Editorial Staff: Levodopa-tricyclic antidepressant interaction (drug consult). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)Google Scholar
  18. 18.
    Graber MA, Hoehns B, Perry PJ: Sertraline-phenylzine drug interaction: A serotonin syndrome reaction. Ann Pharmacother 1994; 28:732–735Google Scholar
  19. 19.
    Brannan SK, Talley BJ, Bowden CL: Sertraline and isocarboxazid cause a serotonin syndrome [letter]. J Clin Psychopharmacol 1994; 14:144–145Google Scholar
  20. 20.
    Beasley CM, Masica DN, Heiligenstein JH, et al.: Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993; 13:312–320Google Scholar
  21. 21.
    Bhatara VS, Bandettini FC: Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993; 12:222–225Google Scholar
  22. 22.
    Coplan JD, Gorman JM: Detectable levels of fluoxetine metabolites after discontinuation: An unexpected serotonin syndrome [letter]. Am J Psychiatry 1993; 150:837Google Scholar
  23. 23.
    Jermain DM, Hughes PL, Follender AB: Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992; 26:1300Google Scholar
  24. 24.
    Montastruc JL, Chamontin B, Senard JM, et al.: Pseudophaechromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341:555Google Scholar
  25. 25.
    Sternbach H: Danger of MAOI therapy after fluoxetine withdrawal [letter]. Lancet 1988; Oct:850–851Google Scholar
  26. 26.
    Toyama SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? [letter]. Ann Pharmacother 1994; 28:405–406Google Scholar
  27. 27.
    Abuzzahab FS: Combination therapy: Monoamine oxidase inhibitors and bupropion HCL [abstract]. Neuropsychopharmacology 1994; 10(35, Part 2):74SGoogle Scholar
  28. 28.
    Dooneief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49:305–307Google Scholar
  29. 29.
    Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG: Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27–31Google Scholar
  30. 30.
    Andersen J, Aabro E, Gulmann N, et al.: Antidepressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62:210–219Google Scholar
  31. 31.
    Ahlskog JE: Parkinson's disease: Update on pharmacologic options to slow progression and treat symptoms. Hosp Formul 1992; 27:146–163Google Scholar
  32. 32.
    Cohen G, Spina MB: Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26:689–690Google Scholar
  33. 33.
    Hurley SC: Tricyclic antidepressants-induced abnormal movements (drug consult). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)Google Scholar
  34. 34.
    DRUGDEX editorial staff. Amoxapine (drug evaluation monograph). In: Gelman CR, Rumack BH, eds. DRUGDEX Information System. Denver: Micromedex (edition expired 5/90)Google Scholar
  35. 35.
    Fahn S: Parkinsonism. In: Wyngaarden JB, Smith LH, eds. Cecil Textbook of Medicine, 18th ed. Philadelphia: WB Saunders; 1988:2143–2147Google Scholar
  36. 36.
    Strang RR: Imipramine in treatment of parkinsonism: A double-blind placebo study. Br Med J 1965; 2:33–34Google Scholar
  37. 37.
    Laitinen L: Desipramine in treatment of Parkinson's disease. Acta Neurol Scand 1969; 45:109–113Google Scholar

Copyright information

© American Academy of Clinical Psychiatrists 1997

Authors and Affiliations

  • Janet L. Ritter
    • 1
  • Bruce Alexander
    • 2
  1. 1.University of Washington Medical Center—RooseveltSeattle
  2. 2.Department of Veterans Affairs Medical CenterIowa City

Personalised recommendations